The global cardiovascular therapeutics market is expected to grow at a CAGR of 4.24% during the forecast period. Major vendors in the global cardiovascular therapeutics market include Astellas Pharma Inc., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd., among others. As per the latest market research report published by Technavio, the global cardiovascular therapeutics market size has the potential to grow by USD 16.19 billion during 2020-2024. Get the free sample report below for the detailed information.
Download the free sample report @ http://bit.ly/2M6tHOC
Vendors are increasingly focusing on new product launches to strengthen their position in the market. For instance, Astellas Pharma Inc., in July 2019, the company launched SMYRAF tablets for the treatment of rheumatoid arthritis in patients who have an inadequate response to conventional therapies. Eli Lilly and Co., in April 2019, the company announced its plan to launch a low-priced version of HUMALOG.
Similarly, GlaxoSmithKline Plc, in May 2019, the company announced that it had received regulatory approval for Shingrix in China. The National Medical Products Administration (NMPA) had approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years and above. Johnson & Johnson Services Inc., in April 2019, the company received the US FDA approval for BALVERSA for the treatment of urothelial carcinoma with certain fibroblast growth factor receptor genetic alterations. Hence, the increasing number of new product launches is expected to propel the growth of the global cardiovascular therapeutics market during the forecast period. To know the complete and in-depth analysis and forecast of this market get the complete report by clicking the link below.
Get the Complete Report @ http://bit.ly/2sD8UeZ
Comments